Building a Hepatocyte Lipid Droplet Model
Choose the cell before the protocol
| Cell | Doubling time | Lipid loading | Use when |
|---|---|---|---|
| HepG2 | ~30 h | Efficient, but glycolytic | Screening; not for insulin or gluconeogenesis claims |
| Huh7 | ~24 h | Efficient, heterogeneous | Reporter assays; avoid for metabolic flux |
| Primary human hepatocyte | Non-dividing | Efficient, physiological | Short-term mechanism; ≤ 72 h |
| iPSC-derived hepatocyte | Non-dividing | Moderate; varies by protocol | Genotype-defined questions |
| HepG2/Huh7 in 3D | — | Higher, with polarity | Secretion and architecture |
Caveat on HepG2. The line is a hepatoblastoma derivative with low albumin, low CYP and a glycolytic phenotype. It loads lipid readily, which makes it convenient and misleading: the loading is a property of a proliferating tumour line, not of a hepatocyte. Any claim about hepatocyte lipid handling — export, oxidation, very-low-density lipoprotein assembly — should be confirmed in a model that performs those functions.
The fatty acid composition
| Composition | Total FA | Storage | Injury | Models |
|---|---|---|---|---|
| Oleate only | 200–400 µM | High | Low | Steatosis |
| Palmitate only | 100–400 µM | Low–moderate | High | Lipotoxicity |
| Oleate : palmitate 2:1 | 200–400 µM | High | Moderate | Common MASH induction |
| Oleate : palmitate 1:1 | 200–400 µM | Moderate | Higher | Injury-weighted |
| + free cholesterol | 20–50 µg/mL with FA | Cholesterol crystals | Inflammasome | Specific sub-phenotype |
Oleate is efficiently esterified into triglyceride and stored in large droplets. Palmitate enters the same pathway but exceeds the esterification capacity relative to its flux, so it is routed to ceramide, diacylglycerol and ER stress. Adding oleate therefore increases triglyceride and reduces palmitate toxicity — the paradox the disease pillar describes, reproducible in a well.
Important distinction. A protocol using palmitate alone is a lipotoxicity model, and calling it a steatosis model inverts the result: the lipid content may be lower than in the oleate condition while the injury is higher.
Conjugation and delivery
- Dissolve sodium oleate and sodium palmitate separately in water at 70 °C, or in ethanol at 0.1 M stock.
- Add dropwise to fatty-acid-free BSA (10–15% w/v in PBS) at 37 °C with stirring.
- Adjust to a 3:1–6:1 fatty acid : BSA molar ratio.
- Cool, filter 0.22 µm, and use within a week; freeze aliquots at −20 °C.
- Add to medium to reach the target total fatty acid concentration; do not exceed 1% v/v of vehicle.
| Parameter | Why it matters |
|---|---|
| FA-free BSA | Residual fatty acids dominate at low palmitate |
| Molar ratio | Sets the free (unbound) concentration, which is the active fraction |
| Filtration | Crystals are phagocytosed and produce artefactual effects |
| Vehicle matched | Ethanol and BSA both change baseline lipid handling |
Caveat on "200 µM palmitate". Two laboratories using that nominal concentration at different BSA ratios can differ several fold in free palmitate. The ratio, not the concentration, is the variable to report.
Timing and refresh
| Day | Manipulation | Readout |
|---|---|---|
| −1 | Seed to 70–80% confluence | — |
| 0 | Add fatty acids in low-serum medium (1–2% FBS) | Baseline lipid |
| 1 | Refresh fatty acids | Lipid accumulation |
| 2 | Readout: lipid, viability, injury | Steatosis established |
| 3–4 | Extended exposure | Injury and ER stress |
| 5+ | Co-culture with stellate cells | Activation markers |
Loading saturates. In most protocols triglyceride peaks at 48–72 h and then plateaus or falls as lipotoxicity reduces cell number. A 96-hour timepoint is therefore not "more steatosis"; it is a different population.
Readout note. Normalise lipid to cell number or DNA, not to well. A condition with 30% fewer cells can show less lipid per well and more per cell, and the two conclusions are opposite.
Readouts and their timing
| Readout | Earliest change | Confounder |
|---|---|---|
| BODIPY area per cell | 12–24 h | Droplet size versus number |
| Triglyceride mass | 24 h | Esterification only |
| Lipid species (DAG, ceramide) | 24–48 h | Requires mass spectrometry |
| LDH release | 24–48 h | Necrosis and apoptosis both |
| Caspase-3/7 | 24–48 h | Does not exclude other programmes |
| CHOP / XBP1s | 12–24 h | Response, not death |
| Albumin secretion | Falls with dedifferentiation | Not a lipid readout |
| ApoB / triglyceride secretion | 24–48 h | The retention measurement |
Important distinction. Retention is the disease-relevant quantity: lipid accumulates when uptake and synthesis exceed export and oxidation. A model that increases triglyceride without measuring export has shown accumulation, not retention.
QC gates
A model is usable if all four pass:
- Differentiation state — albumin and, where relevant, CYP expression at the time of treatment.
- Loading efficiency — ≥ 70% of cells with visible droplets; report the distribution, not a representative image.
- Viability — ≥ 85% at the readout timepoint, otherwise the lipid value is a surviving-subpopulation value.
- Vehicle equivalence — BSA- and ethanol-matched controls show no lipid accumulation.
Failing gate 3 is the most common reason a "steatosis model" is actually a selection experiment.
Failures that recur
- • Palmitate-only protocol labelled steatosis.
- • Triglyceride as the efficacy endpoint — it can fall while DAG and free cholesterol rise.
- • No cell-number normalisation.
- • Lipid readout by representative image only. Quantify per cell, with a distribution.
- • BSA ratio unreported.
- • Long exposure with falling viability read as increased steatosis.
- • Fibrosis claimed from a monoculture. There are no stellate cells.
Where this connects
- • MASH cell models article supplies the compartment and cell-choice logic.
- • Lipid pillar supplies the species and esterification rules.
- • Disease pillar supplies the readout frame: steatosis, activity and fibrosis are separate claims.
- • Palmitate handling at the biophysical level is treated in the lipid-pillar article on palmitate and BSA.
Scientific interpretation and experimental design
- • The ratio is the model. Oleate stores, palmitate injures.
- • Report free fatty acid exposure. Ratio plus concentration.
- • Normalise to cells, not wells.
- • Check viability at the readout. Otherwise it is a selection experiment.
- • Measure export to claim retention.
- • Quantify droplets as a distribution.
- • Stop at the compartment boundary. No stellate cells, no fibrosis claim.
Selected references for further reading
- • Ricchi M, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. Journal of Gastroenterology and Hepatology. 2009;24:830–840.
- • Listenberger LL, et al. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. PNAS. 2003;100:3077–3082.
- • Gómez-Lechón MJ, et al. A human hepatocellular in vitro model to investigate steatosis. Chemico-Biological Interactions. 2007;165:106–116.
- • Friedman SL, et al. Mechanisms of NAFLD development and therapeutic strategies. Nature Medicine. 2018;24:908–922.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »